FMG Pharma Pipeline
A disciplined pathway from discovery to product,
designed to translate science into measurable outcomes
DISCOVERY
PRECLINICAL
CLINICAL
PRODUCT
FMG001
Preclinical
Metabolic dysfunction associated steatotic liver disease (MASLD/MASH)
FMG001 is a new chemical entity (NCE) derived from FMG’s proprietary epicatechin technology. It is in preclinical development as a small-molecule candidate targeting metabolic dysfunctionassociated steatotic liver disease (MASLD/MASH).
DISCOVERY
PRECLINICAL
CLINICAL
PRODUCT
FMG002
Preclinical
Cutaneous complications of diabetes (diabetic dermatology / wound healing)
FMG002 is a new chemical entity (NCE) developed as a topical formulation from FMG’s proprietary epicatechinderived platform. It is in preclinical development for cutaneous complications associated with diabetes, including challenges in wound healing.
DISCOVERY
PRECLINICAL
CLINICAL
PRODUCT
FMG003
Preclinical
Dyslipidemia and cardiometabolic disease
FMG003 is an oral preclinical candidate based on FMG’s proprietary epicatechinderived technology. It is in development for dyslipidemia and associated cardiometabolic conditions.
Cartera de productos nutracéuticos
Cada fórmula se basa en investigaciones revisadas por pares sobre la función mitocondrial, el NAD+, el estrés oxidativo y la bioenergética.
Mitozz
Mitozz un complemento alimenticio formulado a base de (-)-epicatechin altamente purificada (-)-epicatechin favorecer la salud mitocondrial, la energía celular y un envejecimiento saludable. Está diseñado para personas que desean reforzar los sistemas energéticos naturales del organismo mediante un enfoque nutracéutico basado en la ciencia.
Respaldado por más de 60 estudios publicados por nuestro equipo
